|Número de publicación||US20060041242 A1|
|Tipo de publicación||Solicitud|
|Número de solicitud||US 11/168,752|
|Fecha de publicación||23 Feb 2006|
|Fecha de presentación||27 Jun 2005|
|Fecha de prioridad||31 Oct 2001|
|También publicado como||US6944497, US7632225, US7815597, US20030082507, US20060041184, US20060041221|
|Número de publicación||11168752, 168752, US 2006/0041242 A1, US 2006/041242 A1, US 20060041242 A1, US 20060041242A1, US 2006041242 A1, US 2006041242A1, US-A1-20060041242, US-A1-2006041242, US2006/0041242A1, US2006/041242A1, US20060041242 A1, US20060041242A1, US2006041242 A1, US2006041242A1|
|Cesionario original||Medtronic, Inc.|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (23), Citada por (26), Clasificaciones (18)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This application is a Divisional application of U.S. application Ser. No. 10/001,751, filed Oct. 31, 2001. The entire content of this U.S. Application is incorporated herein by reference.
The invention relates to therapeutic treatment of stuttering. More particularly, the invention relates to treating stuttering via neural stimulation and drug therapy techniques.
Stuttering is a speech-disfluency problem that can have significant developmental and social impacts upon stuttering individuals. Stuttering can include repetitions of parts of words and/or whole words, prolongation of sounds, interjections of sounds or words, and unduly prolonged pauses.
Conventional stuttering treatment techniques typically focus on alerting the patient that stuttering is occurring and having the patient try to modify their breathing and/or speech patterns in an attempt to avoid stuttering. For instance, U.S. Pat. No. 4,020,567, entitled Method and Stuttering Therapy Apparatus, issued to Webster on May 3, 1977, discloses a system for helping individuals determine when they are stuttering. The system generates an electrical signal based on the person's speech and uses the signal to detect certain speech characteristics corresponding to stuttering. A first embodiment detects speech onset errors during the first 100 milliseconds of syllable pronunciation. In a second embodiment, stuttering is detected by evaluating the rate of change in the amplitude of the person's speech. An LED is illuminated to notify a system-user that stuttering is occurring. The system disclosed by Webster is intended for use by stutterers while they practice learning not to stutter.
U.S. Pat. No. 4,662,847, entitled Electronic Device and Method for the Treatment of Stuttering, issued to Blum on May 5, 1987, discloses an electronic device for treating stuttering. The device transmits electronic speech signals from a microphone to an earphone through two paths. One path is synchronous. The other path is asynchronous. During normal speech, the synchronous speech signal is transmitted to the earphone. At any pause in phonation, the device switches to the asynchronous path and transmits speech in a delayed auditory feedback mode until a change in the user's speech occurs.
U.S. Pat. No. 4,784,115, entitled Anti-Stuttering Device and Method, issued to Webster on Nov. 15, 1988, discloses an anti-stuttering device for enhancing speech fluency. The device detects vocal pulses generated by the opening and closing of a speaker's vocal folds. Electrical signals representative of the vocal pulses are transmitted to a receiver in the speaker's sealed ear canal where these signals are reproduced as audio pulses. The device reduces stuttering by providing an early indication of the characteristics of the speaker's voice via audio pulses. The audio pulses produce a resonant effect within the person's ear canal.
U.S. Pat. No. 5,794,203, entitled Biofeedback System for Speech Disorders, issued to Kehoe on Aug. 11, 1988, discloses a biofeedback system for speech disorders that detects disfluent speech and provides auditory feedback to enable fluent speech. The disfluent-speech detector can be either an electromyograph (EMG) or an electroglottograph (EGG). EMG is a system that measures the electrical activities of muscles through electrodes attached to a person's body. EGG records the opening and closing of a person's vocal folds. EGG's use two electrodes on a person's neck and measure the resistance between the electrodes. This resistance changes as the vocal folds open and close. An EGG can show the frequency of the vocal folds. This is the fundamental pitch of the user's voice, without the harmonics produced by the nasal cavities, mouth, and the like.
The system disclosed by Kehoe includes an electronic controller connected to an EMG and frequency-altered auditory feedback (FAF) circuit. The controller receives data from the EMG regarding muscle tension in the user's vocal cords, masseter, and/or other speech-production muscles. The controller then controls the pitch of the FAF circuit in accordance with the user's muscle tension. The user wears a headset with a microphone and headphones. Three EMG electrodes are taped onto the user's neck and/or jaw. When the user speaks fluently, with speech-production muscles relaxed, the user's hears his or her voice shifted lower in pitch. This downward-shifted pitch is relaxing and pleasant, sort of like hearing James Earl Jones speak. If the user's speech-production muscles are abnormally tense, however, the user will hear his or her voice shifted higher in pitch.
U.S. Pat. No. 6,231,500, entitled Electronic Anti-Stuttering Device Providing Auditory Feedback and Disfluency-Detecting Biofeedback, issued to Kehoe on May 15, 2001, is a continuation-in-part of U.S. Pat. No. 5,794,203. The Kehoe '500 patent discloses micropower impulse radar (MIR) as an alternative to EMG biofeedback for monitoring a user's muscle activity to detect disfluency. MIR is short-range radar, using commonly available microchips. Unlike other radar, MIR is small and inexpensive. A small sensor for monitoring laryngeal activity could be taped to a user's throat.
Conventional treatment techniques for treating stuttering typically do not use neurostimulation and/or drug delivery devices. These types of devices, however, are capable of treating a number of neurological disorders as well as symptoms of those disorders. In the context of neurostimulators, an electrical lead having one or more electrodes is typically implanted near a specific site in the brain of a patient. The lead is coupled to a signal generator that delivers electrical energy through the electrodes and creates an electrical field causing excitation of the nearby neurons to directly or indirectly treat the neurological disorder or symptoms of the disorder. In the context of a drug delivery system, a catheter coupled to a pump is implanted near a treatment site in the brain. Therapeutics are delivered to the treatment sites in predetermined dosages through the catheter.
In an article entitled Cessation of Stuttering After Bilateral Thalamic Infarction,-A. Muroi et al. describe their observation of a patient who, after paramedian thalamic infarction, experienced cessation of stuttering. Neurology, vol. 53, pp. 890-91 (Sep. (1 of 2) 1999. In this article, A. Muroi et al. state that neuroimaging studies indicate that the occlusion of a single artery, the mesencephalic artery, have given rise to the infarction in the bilateral medial thalamus and rostral mesencephalic tegmentum. Further, in developmental stuttering, regional cerebral blood flow (rCBF) was observed as relatively increased in the medial and lateral prefrontal areas and in the orbital cortices, and also in the supplementary motor area (SMA) and the superior lateral premotor cortex. A. Muroi et al. then discuss a study by Nagafuchi and Takahashi in which a patient started to stutter after an infarct in the SMA. Another article, by Abe et al., describes a case of stuttering-like repetitive speech disorder after paramedian thalamomesencephalic infarction. Yet another article, by Andy and Bhatnager, reported that stuttering was elicited by destruction of the centromedian (CM) in one case; they also found that stimulation of the same region alleviated the acquired stuttering in another case. The work reported by Andy and Bhatnagar related only to adult onset, acquired stuttering, due to the presence of cortical or subcortical pathologies (related to a central pain syndrome), but did not involve the more common form of developmental stuttering. Further, there is no teaching in their work on the application of DBS or drug delivery for the chronic treatment of developmental stuttering as a disorder of the motor system. The dorsomedial (DM) nuclei and CM, which were involved in the case reported by A. Muroi et al., are reciprocally connected to the lateral prefrontal area and SMA, respectively. In light of these studies and the case reported by A. Muroi et al., the A. Muroi et al. article speculates that disordered function of the SMA-CM circuit or DM-lateral prefrontal cortex is responsible for developmental and acquired stuttering. Therefore, it may be possible to treat either developmental or acquired stuttering by stimulation or drug delivery of the neural circuits involved in stuttering.
Based on the foregoing, there is a need for stuttering-treatment techniques that use neural stimulation and/or drug delivery to target the neurological underpinnings of stuttering.
The invention is directed toward various stuttering-treatment techniques using neural stimulation and/or drug delivery. In accordance with various inventive principles, a catheter is coupled to an implantable pump for infusing therapeutic dosages of at least one drug. At least one implantable electrode is coupled to a signal generator for delivering electrical stimulation. The invention may include various permutations and/or combinations of the following steps: implanting the one or more electrodes adjacent to a first predetermined site in the brain; implanting the catheter so that the discharge portion lies adjacent to a second predetermined site in the brain; coupling the proximal end of the implanted electrode to the signal generator; coupling the catheter to the pump; and operating the signal generator and the pump to stimulate or inhibit neurons of the first and second sites in the brain by delivering electrical stimulation to the first site and by delivering one or more drugs to the second predetermined site. The first and/or second predetermined sites can be: the supplementary motor area, the perisylvian speech-language cortex, the centromedian circuit, the dorsomedial nuclei, the lateral prefrontal circuit, the mesothalamic reticular formation, the basal ganglia, or other paramedian thalamic and midbrain nuclei and fiber tracts including, but not limited to the red nucleus, the habenulointerpeduncular tract, the prerubral area, the zona incerta, the thalamic primary sensory relay nuclei (e.g., ventrooral nucleus, ventrolateral nucleus), the parafasicular nucleus, and the intralaminar nucleus.
In accordance with the invention, the stuttering treatment may be performed via periodic, such as once per week, transcranial magnetic stimulation of a predetermined site of a patient's brain for a predetermined duration, such as 30 minutes. The transcranial-magnetic-stimulation site is delivered to: the supplementary motor area, the perisylvian speech-language cortex, the centromedian circuit, the dorsomedial nuclei, the lateral prefrontal circuit, the mesothalamic reticular formation, the basal ganglia, or other paramedian thalamic and midbrain nuclei and fiber tracts including, but not limited to the red nucleus, the habenulointerpeduncular tract, the prerubral area, the zona incerta, the thalamic primary sensory relay nuclei (e.g., ventrooral nucleus, ventrolateral nucleus), the parafasicular nucleus, and the intralaminar nucleus.
A system, in accordance with the invention, for therapeutically treating stuttering in a patient is disclosed. The system includes: a signal generator; at least one implantable lead, coupled to the signal generator, for delivering electrical stimulation to at least one predetermined site of the patient's brain; a sensor, located near the patient's vocal folds, for generating a signal responsive to activity of the patient's vocal folds; a controller that adjusts at least one stimulation parameter in response to the signal from the sensor. The controller could detect when the patient starts speaking and then start the electrical stimulation in response to that patient having started to speak. The controller could then stop the electrical stimulation a predetermined amount of time after the patient started speaking. The sensor could be an electromyographic sensor, an electroglottographic sensor, or a microphone, which could be implanted within the patient's body. The controller could use a speech-recognition algorithm for detecting stuttering based on the signal received from the sensor.
Other advantages, novel features, and further scope of applicability of the invention will be set forth in the following detailed description.
The neurogenic basis of stuttering is not well understood, but an analogy can be drawn between stuttering and motor tremor in a person's extremities or axial musculature. It is know that in some forms of tremor the occurrence of abnormal neural activity in specific brain regions (e.g., thalamus) is associated with the presence of tremor. It is also known that treatment of these regions with electrical stimulation or drug delivery can reduce or abolish tremor. The structures that are apparently involved in stuttering are the supplementary motor area, (SMA), the centromedian circuit (CM circuit), the dorsomedial nuclei (DM nuclei), the lateral prefrontal circuit, and other paramedian thalamic and midbrain nuclei, and by analogy to tremor, it is hypothesized that abnormal neural activity in these structures and circuits is associated with the presence of stuttering.
The thalamus and cortex are connected by a network of parallel neural circuits that send information in both directions to ultimately control thoughts, emotions, motor behaviors, and various other higher level functions. Each of the various types of functions appears to have discrete anatomical circuit associated with them. If abnormal patterns of neural activity (e.g., too much or too little activity) arise in a specific circuit due to disease, trauma, or developmental causes, the result is often a clinical symptom associated with the specific functional area. For instance, obsessive-compulsive disorder is thought to be due to hyperactivity in the loop connecting orbital-frontal cortex with the medial thalamus. Tremor in a specific body region appears to arise due to over activity in the loop between the basal ganglia, thalamus and the motor cortex subserving that body part. Similarly, stuttering may be related to abnormal activity in the basal ganglia and thalamo-cortical loops that control the production of speech.
It has been hypothesized that two such loops are involved in language production and therefore in the dysfunction of stuttering: an “outer” linguistic loop, which controls the selection of speech information, and an “inner” motor loop that controls the actual production of speech sounds via control of the vocal apparatus. The linguistic loop appears to be mediated by neural circuits in the perisylvian speech-language cortex, and the motor loop by cortico-striatal-thalamo-cortical circuits. A disruption in timing between these circuits has been suggested as a possible mechanism of stuttering. By applying electrical stimulation and or drug delivery within these circuits, it may be possible to re-establish the proper timing relationships and thereby reduce or eliminate stuttering.
For example, the supplementary motor area (SMA), part of the motor loop, can be thought of as generating a signal indicative of the intention to do something, such as begin speaking. That signal then gets passed to the motor cortex, which is a part of the brain that sends a corresponding signal to a person's muscles, including a person's vocal cords, to do something, such as making speech sounds.
Disruption of the appropriate precursor signal from the SMA may be responsible for a stutterer's inability to speak fluently when they are starting to say something. Such a disruption may also be responsible for a stutterer's inability to break out of a loop in which the same sound is being unintentionally repeated and the inability to progress to the next stage of speaking, which occurs in fluent speech.
This invention includes treatment techniques for ameliorating stuttering by influencing levels of activity in various neuronal loops associated with stuttering. These techniques include drug delivery, electrical and magnetic stimulation, and/or closed loop feedback systems for detecting the occurrence of speech or stuttering.
As depicted in
The distal end of lead 22A terminates in a stimulation electrode located at a predetermined area of the brain, B. The distal end of lead 22A is implanted using stereotactic techniques that are well known by those skilled in the art. The physician determines the number of electrodes needed for the particular treatment.
The combined catheter electrode 322 terminates with a cylindrical hollow tube 322A having a distal end implanted into a predetermined location of a patient's brain, B. The distal end of tube 322A is implanted using stereotactic techniques well known by those skilled in the art. Tube 322A includes an outer cylindrical insulation jacket (not shown) and an inner insulation jacket (not shown) that defines a cylindrical catheter lumen. A multifular coil of wire, multiflar stranded wire or flexible printed circuit is embedded in tube 322A (not shown).
Trans-cranial magnetic stimulation could also be used as a means to deliver therapeutic stimulation to the nervous system to treat stuttering. This magnetic stimulation would tend to be more of a clinical application as opposed to a portable and/or human-implantable device. In accordance with the invention, a patient's stuttering could be treated periodically, such as once per week, via trans-cranial magnetic stimulation of the supplementary motor area, (SMA), the centromedian circuit (CM circuit), the dorsomedial nuclei (DM nuclei), the lateral prefrontal circuit, and other paramedian thalamic and midbrain nuclei and fiber tracts including, but not limited to the red nucleus, the habenulointerpeduncular tract, the prerubral area, the zona incerta, the thalamic primary sensory relay nuclei (e.g., ventrooral nucleus, ventrolateral nucleus), the parafasicular nucleus, and the intralaminar nucleus. The Magpro stimulator available from Medtronic, Inc. of Minneapolis Minn. is an example of a suitable magnetic stimulator. Magnetic stimulators of this type are capable of causing electrical current flow in particular regions of a patient's brain thereby activating specific neural structures or circuits. Such magnetic stimulation has been used clinically as a diagnostic tool to evaluate the condition of the motor system, and therapeutically to treat disorders such as depression.
Several other techniques, which are well known in the art, could also be used in accordance with the invention for detecting speech disfluency. For instance, as described in more detail above, each of U.S. Pat. Nos. 4,020,567, 5,794,203, and 6,231,500, which are incorporated herein by reference, disclose speech-disfluency-detection devices that could be used with this invention.
The amount and type of stimulation delivered in accordance with the invention may be controlled based upon analysis of the output from a sensor, such as sensor 130 shown in
An exemplary computer algorithm is shown in
For some types of sensors, a microprocessor and analog to digital converter will not be necessary. An appropriate elect filter can be used to filter the output from sensor 130 to provide a control signal for signal generator 16. An example of such a filter is found in U.S. Pat. No. 5,259,387 “Muscle Artifact Filter, Issued to Victor de Pinto on Nov. 9, 1993, incorporated herein by reference.
A modified form of the ITREL II® signal generator can be used to achieve closed-loop electrical stimulation, which is schematically depicted in
Programming a value to a programmable frequency generator 208, using bus 202, controls the stimulus pulse frequency. The programmable frequency generator provides an interrupt signal to microprocessor 200 through an interrupt line 210 when each stimulus pulse is to be generated. The frequency generator may be implemented by model CDP1878 sold by Harris Corporation. The amplitude for each stimulus pulse is programmed to a digital to analog converter 218 using bus 202. The analog output is conveyed through a conductor 220 to an output driver circuit 224 to control stimulus amplitude. Microprocessor 200 also programs a pulse width control module 214 using bus 202. The pulse width control provides an enabling pulse of duration equal to the pulse width via a conductor. Pulses with the selected characteristics are then delivered from signal generator 16 through cable 22 and lead 22A to the target locations of a brain B.
Microprocessor 200 executes an algorithm shown in
The algorithm for selecting parameters is different depending on whether the clinician has chosen to block the neural activity at the stimulation target or facilitate the neural activity.
The algorithm uses the clinician programmed indication of whether the neurons at the particular location of the stimulating electrode are to be facilitated or blocked in order to decide which path of the parameter selection algorithm to follow (step 420,
If the frequency parameter is at the maximum, the algorithm next increases the pulse width in step 426 (
If, on the other hand, the stimulation electrode is placed in a location which the clinician would like to activate in order to alleviate stuttering, the algorithm would follow a different sequence of events. In the preferred embodiment, the frequency parameter would be fixed at a value chosen by the clinician to facilitate neuronal activity in step 430 (
It is desirable to reduce parameter values to the minimum level needed to establish the appropriate level of neuronal activity in, for example, the target brain nucleus. Superimposed on the algorithm just described is an additional algorithm to readjust all the parameter levels downward as far as possible. In
While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims and their equivalents.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US3566858 *||4 Nov 1968||2 Mar 1971||Zenith Radio Corp||Antistuttering therapeutic device|
|US4020567 *||16 Oct 1974||3 May 1977||Webster Ronald L||Method and stuttering therapy apparatus|
|US4662847 *||29 Nov 1985||5 May 1987||Blum Arthur M||Electronic device and method for the treatment of stuttering|
|US4692147 *||19 Jul 1985||8 Sep 1987||Medtronic, Inc.||Drug administration device|
|US4784115 *||16 Jun 1986||15 Nov 1988||Webster Ronald L||Anti-stuttering device and method|
|US4909261 *||13 Feb 1989||20 Mar 1990||Syracuse University||Tracking multielectrode electroglottograph|
|US5111814 *||6 Jul 1990||12 May 1992||Thomas Jefferson University||Laryngeal pacemaker|
|US5113859 *||25 Jun 1990||19 May 1992||Medtronic, Inc.||Acoustic body bus medical device communication system|
|US5259387 *||9 Sep 1991||9 Nov 1993||Quinton Instrument Company||ECG muscle artifact filter system|
|US5478304 *||18 Nov 1993||26 Dic 1995||Webster; Ronald L.||Anti-sturrering device and method|
|US5683422 *||25 Abr 1996||4 Nov 1997||Medtronic, Inc.||Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation|
|US5713923 *||13 May 1996||3 Feb 1998||Medtronic, Inc.||Techniques for treating epilepsy by brain stimulation and drug infusion|
|US5794203 *||22 Mar 1994||11 Ago 1998||Kehoe; Thomas David||Biofeedback system for speech disorders|
|US5843142 *||27 Mar 1997||1 Dic 1998||Sultan; Hashem||Voice activated loco motor device and method of use for spinal cord injuries|
|US5940798 *||5 Feb 1998||17 Ago 1999||Scientific Learning Corporation||Feedback modification for reducing stuttering|
|US5961443 *||1 Abr 1997||5 Oct 1999||East Carolina University||Therapeutic device to ameliorate stuttering|
|US6094598 *||25 Abr 1996||25 Jul 2000||Medtronics, Inc.||Method of treating movement disorders by brain stimulation and drug infusion|
|US6128538 *||29 Nov 1999||3 Oct 2000||Neuropace, Inc.||Means and method for the treatment of neurological disorders|
|US6227203 *||9 Sep 1998||8 May 2001||Medtronic, Inc.||Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion|
|US6231500 *||2 May 1995||15 May 2001||Thomas David Kehoe||Electronic anti-stuttering device providing auditory feedback and disfluency-detecting biofeedback|
|US6263237 *||14 Feb 2000||17 Jul 2001||Medtronic, Inc.||Techniques for treating anxiety disorders by brain stimulation and drug infusion|
|US6463328 *||10 Ene 2000||8 Oct 2002||Michael Sasha John||Adaptive brain stimulation method and system|
|US6539263 *||7 Jun 2000||25 Mar 2003||Cornell Research Foundation, Inc.||Feedback mechanism for deep brain stimulation|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US7605249||25 Nov 2003||20 Oct 2009||Medtronic, Inc.||Treatment of neurodegenerative disease through intracranial delivery of siRNA|
|US7618948||19 Oct 2005||17 Nov 2009||Medtronic, Inc.||Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA|
|US7699803||3 Ene 2008||20 Abr 2010||Medtronic Vascular, Inc.||Devices and methods for injection of multiple-component therapies|
|US7732591||8 Ago 2006||8 Jun 2010||Medtronic, Inc.||Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna|
|US7815597 *||27 Jun 2005||19 Oct 2010||Medtronic, Inc.||System and method of treating stuttering by neuromodulation|
|US7819842||21 Nov 2006||26 Oct 2010||Medtronic, Inc.||Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites|
|US7829694||25 May 2004||9 Nov 2010||Medtronic, Inc.||Treatment of neurodegenerative disease through intracranial delivery of siRNA|
|US7902352||9 Ago 2006||8 Mar 2011||Medtronic, Inc.||Isolated nucleic acid duplex for reducing huntington gene expression|
|US7959612||21 Abr 2008||14 Jun 2011||Medtronic Vascular, Inc.||Dual syringe injector system|
|US7988668||21 Nov 2006||2 Ago 2011||Medtronic, Inc.||Microsyringe for pre-packaged delivery of pharmaceuticals|
|US8016814||10 Mar 2008||13 Sep 2011||Medtronic Vascular, Inc.||Guidewires and delivery catheters having fiber optic sensing components and related systems and methods|
|US8057426||3 Ene 2008||15 Nov 2011||Medtronic Vascular, Inc.||Devices and methods for injection of multiple-component therapies|
|US8058251||31 Oct 2007||15 Nov 2011||Kaemmerer William F||Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA|
|US8119611||27 Ago 2009||21 Feb 2012||Medtronic, Inc.||Treatment of neurodegenerative disease through intracranial delivery of SIRNA|
|US8258112||10 Sep 2009||4 Sep 2012||Medtronic, Inc||Methods and sequences to suppress primate huntington gene Expression|
|US8324367||16 Oct 2009||4 Dic 2012||Medtronic, Inc.||Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity|
|US8353892||4 May 2011||15 Ene 2013||Medtronic Vascular, Inc.||Devices and methods for controlled-depth injection|
|US8396558 *||4 Feb 2010||12 Mar 2013||University Of Maryland, Baltimore||Methods for treating central pain syndrome and other pain related pathologies|
|US8415319||23 Sep 2011||9 Abr 2013||Medtronic, Inc.||Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA|
|US8618069||8 Oct 2009||31 Dic 2013||Medtronic, Inc.||Devices, systems and methods for improving memory and/or cognitive function through brain delivery of siRNA|
|US8957198||16 Feb 2011||17 Feb 2015||Medtronic, Inc.||Compositions, devices and methods for treatment of Huntington's disease through intracranial delivery of sirna|
|US9133517||15 Sep 2009||15 Sep 2015||Medtronics, Inc.||Methods and sequences to preferentially suppress expression of mutated huntingtin|
|US20060041221 *||27 Jun 2005||23 Feb 2006||Medtronic, Inc.||System and method of treating stuttering by neuromodulation|
|US20060253068 *||20 Abr 2005||9 Nov 2006||Van Bilsen Paul||Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart|
|US20100204751 *||12 Ago 2010||University Of Maryland, Baltimore||Methods for Treating Central Pain Syndrome and Other Pain Related Pathologies|
|WO2008063759A2 *||4 Oct 2007||29 May 2008||Medtronic Inc||A method of increasing retention, survival and proliferation of transplanted cells in vivo|
|Clasificación de EE.UU.||604/503, 607/3, 604/67, 600/23|
|Clasificación internacional||A61M5/142, A61N1/32, A61M31/00, A61F5/58, A61M5/172|
|Clasificación cooperativa||A61M5/1723, A61F5/58, A61M5/14276, A61M2210/0693, A61N1/32|
|Clasificación europea||A61M5/172B, A61N1/32, A61F5/58, A61M5/142P10|